Press Coverage

FDA Clearance for Cellvizio + Pafolacianine for Molecular Imaging

9 May 2022

The US FDA has granted 510(k) clearance (K220477) for the use of the Cellvizio 100 Series platform with a molecular imaging agent called Pafolacianine (Cytalux) for real-time in vivo visualization during endoscopic, laparoscopic, and needle-based procedures, according to Mauna Kea Technologies.

Latest News

Mauna Kea Technologies announces Initiation of Coverage by Allinvest Securities 

Mauna Kea Technologies announces Initiation of Coverage by Allinvest Securities 

Mauna Kea Technologies announces its 2026 financial calendar highlighted by its participation in several investor forums

Mauna Kea Technologies announces its 2026 financial calendar highlighted by its participation in several investor forums

Mauna Kea Technologies Reports Strong Q4 2025 Sales Driven by Accelerated Growth in the U.S. 

Mauna Kea Technologies Reports Strong Q4 2025 Sales Driven by Accelerated Growth in the U.S. 

No results found.